Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE3.0350
- TODAY'S CHANGE (%)0.0950 (3.2313%)
- Bid / Lots3.0300/ 12
- Ask / Lots3.0400/ 12
- Open / Previous Close2.9400 / 2.9400
- Day Range
- 52 Week Range
- Volume564,314
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 2670 | 2.9411 |
| 09:34 ET | 6685 | 3.01 |
| 09:36 ET | 3474 | 2.985 |
| 09:38 ET | 3702 | 2.98 |
| 09:39 ET | 300 | 2.99 |
| 09:41 ET | 555 | 3 |
| 09:43 ET | 2041 | 3.0165 |
| 09:45 ET | 1583 | 3.0089 |
| 09:48 ET | 3281 | 3.01 |
| 09:50 ET | 1161 | 3 |
| 09:52 ET | 2873 | 3.01 |
| 09:54 ET | 600 | 3.02 |
| 09:56 ET | 400 | 3.02 |
| 09:57 ET | 6871 | 3.04 |
| 09:59 ET | 5621 | 3.02 |
| 10:01 ET | 2462 | 3.025 |
| 10:03 ET | 100 | 3.02 |
| 10:06 ET | 4405 | 3.045 |
| 10:08 ET | 863 | 3.045 |
| 10:10 ET | 6400 | 3.04 |
| 10:12 ET | 3667 | 3.045 |
| 10:14 ET | 17760 | 3.035 |
| 10:15 ET | 1558 | 3.015 |
| 10:17 ET | 2669 | 3.025 |
| 10:19 ET | 200 | 3.02 |
| 10:21 ET | 1250 | 3.01 |
| 10:24 ET | 542 | 3.005 |
| 10:26 ET | 1095 | 3.009 |
| 10:30 ET | 300 | 3.01 |
| 10:32 ET | 6906 | 3.015 |
| 10:33 ET | 1233 | 3 |
| 10:35 ET | 5150 | 3.01 |
| 10:37 ET | 985 | 3.02 |
| 10:39 ET | 1244 | 3.015 |
| 10:42 ET | 2837 | 3.02 |
| 10:44 ET | 3176 | 3.045 |
| 10:46 ET | 5571 | 3.035 |
| 10:48 ET | 2360 | 3.05 |
| 10:50 ET | 5035 | 3.045 |
| 10:51 ET | 2973 | 3.03 |
| 10:53 ET | 2176 | 3.04 |
| 10:57 ET | 400 | 3.035 |
| 11:00 ET | 400 | 3.03 |
| 11:02 ET | 2497 | 3.02 |
| 11:04 ET | 1468 | 3.04 |
| 11:06 ET | 327 | 3.0489 |
| 11:08 ET | 1200 | 3.045 |
| 11:09 ET | 1854 | 3.045 |
| 11:11 ET | 1132 | 3.04 |
| 11:13 ET | 100 | 3.04 |
| 11:15 ET | 300 | 3.04 |
| 11:18 ET | 1156 | 3.045 |
| 11:20 ET | 5552 | 3.045 |
| 11:22 ET | 2619 | 3.05 |
| 11:24 ET | 6793 | 3.045 |
| 11:26 ET | 300 | 3.05 |
| 11:27 ET | 749 | 3.045 |
| 11:29 ET | 418 | 3.04 |
| 11:31 ET | 7341 | 3.05 |
| 11:33 ET | 2954 | 3.06 |
| 11:36 ET | 1097 | 3.055 |
| 11:38 ET | 2400 | 3.07 |
| 11:40 ET | 2318 | 3.09 |
| 11:42 ET | 13623 | 3.09 |
| 11:44 ET | 19069 | 3.1 |
| 11:45 ET | 2576 | 3.075 |
| 11:47 ET | 200 | 3.07 |
| 11:49 ET | 486 | 3.055 |
| 11:51 ET | 4502 | 3.05 |
| 11:54 ET | 205259 | 3.065 |
| 11:56 ET | 6528 | 3.08 |
| 11:58 ET | 1582 | 3.075 |
| 12:00 ET | 5748 | 3.08 |
| 12:02 ET | 719 | 3.0707 |
| 12:03 ET | 200 | 3.07 |
| 12:05 ET | 300 | 3.065 |
| 12:07 ET | 1100 | 3.06 |
| 12:09 ET | 608 | 3.05 |
| 12:12 ET | 2824 | 3.05 |
| 12:14 ET | 600 | 3.06 |
| 12:16 ET | 14061 | 3.065 |
| 12:18 ET | 3535 | 3.075 |
| 12:20 ET | 600 | 3.075 |
| 12:21 ET | 1207 | 3.07 |
| 12:23 ET | 700 | 3.075 |
| 12:25 ET | 500 | 3.08 |
| 12:27 ET | 300 | 3.08 |
| 12:30 ET | 400 | 3.075 |
| 12:32 ET | 4408 | 3.075 |
| 12:34 ET | 1800 | 3.06 |
| 12:36 ET | 300 | 3.055 |
| 12:38 ET | 1087 | 3.05 |
| 12:39 ET | 800 | 3.05 |
| 12:41 ET | 973 | 3.05 |
| 12:43 ET | 700 | 3.05 |
| 12:45 ET | 3105 | 3.045 |
| 12:48 ET | 100 | 3.045 |
| 12:50 ET | 3623 | 3.035 |
| 12:52 ET | 796 | 3.035 |
| 12:54 ET | 408 | 3.035 |
| 12:56 ET | 500 | 3.035 |
| 12:57 ET | 4596 | 3.035 |
| 12:59 ET | 1548 | 3.03 |
| 01:01 ET | 816 | 3.03 |
| 01:03 ET | 798 | 3.036 |
| 01:06 ET | 200 | 3.035 |
| 01:08 ET | 7007 | 3.01 |
| 01:15 ET | 100 | 3.01 |
| 01:19 ET | 300 | 3.01 |
| 01:21 ET | 412 | 3.015 |
| 01:24 ET | 6966 | 3.03 |
| 01:26 ET | 1218 | 3.035 |
Sep 16, 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm, from 9:38PM ET on Monday Sep 16, 2024 by Dow Jones
9:38PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Pharmaceuticals Price Target Maintained With a $20.00/Share by Oppenheimer, from 2:03PM ET on Monday Sep 16, 2024 by Dow Jones
2:03PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies, from 7:37AM ET on Monday Sep 16, 2024 by Dow Jones
7:37AM ET on Monday Sep 16, 2024 by Dow JonesZentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies, from 7:00AM ET on Monday Sep 16, 2024 by Dow Jones
7:00AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 209.1M | -1.1x | --- |
XBiotech Inc | 212.3M | -6.2x | --- |
Immutep Ltd | 312.7M | -8.6x | --- |
Acrivon Therapeutics Inc | 216.2M | -2.6x | --- |
Trevi Therapeutics Inc | 217.8M | -8.0x | --- |
Corbus Pharmaceuticals Holdings Inc | 220.6M | -3.1x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 10275 Science Center Drive, Suite 200SAN DIEGO, CA, United States 92121
- Phone
- 858-263-4333
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Interim Chief Financial Officer, Interim Treasurer, Executive Director
- Cam Gallagher
- Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Scientific Officer
- Mark Lackner,
- Chief Medical Officer
- Diana Hausman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $209.1M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-2.75 |
Book Value | $6.18 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -543.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
